EFNB1: A Potential Drug Target and Biomarker (G1947)

Target Name: EFNB1

NCBI ID: G1947

EFNB1

EFNB1: A Potential Drug Target and Biomarker

EFNB1, also known as exenatide, is a medication that is used to treat type 2 diabetes. It is taken as an injection once a week and works by mimicking the effects of insulin to lower blood sugar levels. While EFNB1 has been shown to be an effective treatment for diabetes, there is ongoing research into its potential uses as a drug target and biomarker.

As a drug target, EFNB1 is being investigated for its ability to interact with specific proteins that are involved in the development and progression of diabetes. One of the proteins that is being targeted is the GLUT1 enzyme. GLUT1 is a key regulator of glucose uptake and storage in the body, and is thought to play a role in the development of insulin resistance.

Research has shown that GLUT1 is activated in the body when blood sugar levels are high, and that this activation may contribute to the development of type 2 diabetes. By inhibiting GLUT1 activity, EFNB1 may be able to reduce the risk of developing diabetes or slow down its progression.

In addition to its potential use as a drug target, EFNB1 has also been shown to be a potential biomarker for diabetes. This is because it is associated with the development of certain health problems, such as obesity and cardiovascular disease, that are common in people with diabetes. By using EFNB1 as a biomarker, healthcare professionals may be able to monitor the early stages of diabetes and detect the disease earlier, when it is most treatable.

While EFNB1 is still being investigated as a drug target and biomarker, it is clear that it has the potential to be a valuable tool in the fight against diabetes. With further research, it may be able to not only improve treatment outcomes for people with diabetes, but also serve as a valuable research tool for scientists studying the disease.

Overall, EFNB1 is an intriguing drug that is being investigated for its potential uses as a drug target and biomarker. While more research is needed, it is clear that EFNB1 has the potential to make a significant impact on the treatment of diabetes.

Protein Name: Ephrin B1

Functions: Cell surface transmembrane ligand for Eph receptors, a family of receptor tyrosine kinases which are crucial for migration, repulsion and adhesion during neuronal, vascular and epithelial development (PubMed:8070404, PubMed:7973638). Binding to Eph receptors residing on adjacent cells leads to contact-dependent bidirectional signaling into neighboring cells (PubMed:8070404, PubMed:7973638). Shows high affinity for the receptor tyrosine kinase EPHB1/ELK (PubMed:8070404, PubMed:7973638). Can also bind EPHB2 and EPHB3 (PubMed:8070404). Binds to, and induces collapse of, commissural axons/growth cones in vitro (By similarity). May play a role in constraining the orientation of longitudinally projecting axons (By similarity)

The "EFNB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EFNB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets